Seaport Therapeutics, Inc. (SPTX) Stock
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
About Seaport Therapeutics, Inc.
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Seaport Therapeutics, Inc. is led by CEO Daphne Zohar, employs 58 people, headquartered in US, publicly traded since 2026.
Seaport Therapeutics, Inc. (SPTX) stock trades at $20.61 with a market capitalization of $1.10B. The stock is valued at a negative price-to-earnings (P/E) ratio of -12.49, reflecting a net loss over the last twelve months, price-to-book of 2.61, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $14.85 and $28.38, and currently trades 27.4% below its 52-week high.
On profitability, Seaport Therapeutics, Inc. generates a return on equity (ROE) of -57.34% (negative, reflecting a net loss), return on capital employed of -21.91%.
Official website: www.seaporttx.com
Seaport Therapeutics, Inc. (SPTX) — frequently asked questions
What is Seaport Therapeutics, Inc. (SPTX) stock price today?
Seaport Therapeutics, Inc. (SPTX) is currently trading at $20.61, down 0.72% today.
What is SPTX P/E ratio?
Seaport Therapeutics, Inc.'s P/E ratio is -12.49. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is SPTX return on equity (ROE)?
Seaport Therapeutics, Inc.'s return on equity (ROE) is -57.34%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is Seaport Therapeutics, Inc.'s market cap?
Seaport Therapeutics, Inc. has a market capitalization of $1.10B.
Does SPTX pay a dividend?
Seaport Therapeutics, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does SPTX carry?
Seaport Therapeutics, Inc. has a debt-to-equity ratio of 0.01. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is SPTX's profit margin?
Seaport Therapeutics, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is SPTX in?
Seaport Therapeutics, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is SPTX listed on?
Seaport Therapeutics, Inc. trades on NASDAQ under the ticker SPTX.
What is SPTX's 52-week range?
Over the last year Seaport Therapeutics, Inc. has traded between $14.85 and $28.38.
Related Healthcare Stocks
Popular Stocks
Screens SPTX currently matches
On the figures above, Seaport Therapeutics, Inc. passes the filters for 8 of our ready-made screens, among them Low Debt Stocks, Small Cap Stocks, Debt Free Stocks Under $100. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.